Genentech/Biogen Idec Submit Rituxan sBLAs For Arthritis, Front-Line NHL
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genentech and Biogen Idec’s Rituxan (rituximab) could be approved by February 2006 for aggressive non-Hodgkin’s lymphoma and rheumatoid arthritis.
You may also be interested in...
Genentech Rituxan Aggressive NHL sBLA Will Include Conflicting Survival Data
Genentech’s upcoming Rituxan submission for use in aggressive non-Hodgkin’s lymphoma will likely include trials with conflicting survival data.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product